Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, September 8, 2017
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
[ Fri, Sep 08th 2017
] - WOPRAI
Thu, September 7, 2017
[ Thu, Sep 07th 2017
] - WOPRAI
[ Thu, Sep 07th 2017
] - WOPRAI
[ Thu, Sep 07th 2017
] - WOPRAI
[ Thu, Sep 07th 2017
] - WOPRAI
Gena Wang Initiated (SRPT) at Hold and Held Target at $46 on, Sep 7th, 2017
Gena Wang of Barclays, Initiated "Sarepta Therapeutics, Inc." (SRPT) at Hold and Held Target at $46 on, Sep 7th, 2017.
Gena has made no other calls on SRPT in the last 4 months.
There is 1 other peer that has a rating on SRPT. Out of the 1 peers that are also analyzing SRPT, all agrees with Gena's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $33 on, Thursday, July 20th, 2017
Similar Stocks and Investing Articles
[ Thu, Aug 17th 2017
] - WOPRAI
[ Mon, Aug 07th 2017
] - WOPRAI
[ Thu, Jul 27th 2017
] - WOPRAI
[ Wed, Jul 26th 2017
] - WOPRAI
[ Thu, Jul 20th 2017
] - WOPRAI
[ Thu, Sep 15th 2016
] - WOPRAI
[ Tue, Nov 06th 2012
] - WOPRAI
[ Mon, Nov 05th 2012
] - WOPRAI
[ Thu, Sep 27th 2012
] - WOPRAI
[ Fri, Aug 24th 2012
] - WOPRAI